Switch theme
Sign up to access all valuation multiples
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
1973
17.3K+
LTM Revenue $1.5B
LTM EBITDA $299M
$6.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alkem Laboratories has a last 12-month revenue (LTM) of $1.5B and a last 12-month EBITDA of $299M.
In the most recent fiscal year, Alkem Laboratories achieved revenue of $1.5B and an EBITDA of $352M.
Alkem Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alkem Laboratories valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| Gross Profit | $976M | XXX | $960M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $299M | XXX | $352M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $261M | XXX | $252M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $257M | XXX | $254M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $88.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alkem Laboratories's stock price is INR 5099 (or $60).
Alkem Laboratories has current market cap of INR 610B (or $7.1B), and EV of INR 578B (or $6.8B).
See Alkem Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.8B | $7.1B | XXX | XXX | XXX | XXX | $2.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alkem Laboratories has market cap of $7.1B and EV of $6.8B.
Alkem Laboratories's trades at 4.5x EV/Revenue multiple, and 20.2x EV/EBITDA.
Equity research analysts estimate Alkem Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alkem Laboratories has a P/E ratio of 27.8x.
See valuation multiples for Alkem Laboratories and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.1B | XXX | $7.1B | XXX | XXX | XXX |
| EV (current) | $6.8B | XXX | $6.8B | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | 22.6x | XXX | 20.2x | XXX | XXX | XXX |
| EV/EBIT | 25.9x | XXX | 27.3x | XXX | XXX | XXX |
| EV/Gross Profit | 6.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 27.8x | XXX | 29.4x | XXX | XXX | XXX |
| EV/FCF | 42.2x | XXX | 42.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlkem Laboratories's last 12 month revenue growth is 9%
Alkem Laboratories's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $41K for the same period.
Alkem Laboratories's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alkem Laboratories's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alkem Laboratories and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $41K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alkem Laboratories acquired XXX companies to date.
Last acquisition by Alkem Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Alkem Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alkem Laboratories founded? | Alkem Laboratories was founded in 1973. |
| Where is Alkem Laboratories headquartered? | Alkem Laboratories is headquartered in India. |
| How many employees does Alkem Laboratories have? | As of today, Alkem Laboratories has 17.3K+ employees. |
| Is Alkem Laboratories publicy listed? | Yes, Alkem Laboratories is a public company listed on NSE. |
| What is the stock symbol of Alkem Laboratories? | Alkem Laboratories trades under ALKEM ticker. |
| When did Alkem Laboratories go public? | Alkem Laboratories went public in 2015. |
| Who are competitors of Alkem Laboratories? | Similar companies to Alkem Laboratories include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Alkem Laboratories? | Alkem Laboratories's current market cap is $7.1B |
| What is the current revenue of Alkem Laboratories? | Alkem Laboratories's last 12 months revenue is $1.5B. |
| What is the current revenue growth of Alkem Laboratories? | Alkem Laboratories revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Alkem Laboratories? | Current revenue multiple of Alkem Laboratories is 4.4x. |
| Is Alkem Laboratories profitable? | Yes, Alkem Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alkem Laboratories? | Alkem Laboratories's last 12 months EBITDA is $299M. |
| What is Alkem Laboratories's EBITDA margin? | Alkem Laboratories's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Alkem Laboratories? | Current EBITDA multiple of Alkem Laboratories is 22.6x. |
| What is the current FCF of Alkem Laboratories? | Alkem Laboratories's last 12 months FCF is $160M. |
| What is Alkem Laboratories's FCF margin? | Alkem Laboratories's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Alkem Laboratories? | Current FCF multiple of Alkem Laboratories is 42.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
